Tarsus Pharmaceuticals logo

Tarsus Pharmaceuticals

TARS | NASDAQ
Chart Builder DCF Calculator
$78.68
-$1.60 (-1.99%)
At close: Nov 16, 2026, 4:00 PM ET
$78.16
-$0.52 (-0.66%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.99%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
53.6
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #208/1021 (Top 20%)

Key Statistics

Market Data

Market Cap $3.88B
1D Range
77.39 81.35
52W Range
56.11 90.78

Valuation (TTM)

PE -5.18
PB 37.29
EV/EBITDA -5.20

Valuation (NTM)

Forward PE 77.61
Forward PEG -0.01
Price Target $105.00
Loading financial charts...

Profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigat...

Sector Healthcare
Industry Biotechnology
Employees 370
IPO Date Oct 16, 2020
Fiscal Year January - December

Latest News

Tarsus to Participate in Upcoming Investor Conferences

11 days ago · globenewswire.com

Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals Q3 Earnings Call Highlights

13 days ago · marketbeat.com

Tarsus Pharmaceuticals Q3 Earnings Call Highlights
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

13 days ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Reports Third Quarter 2026 Financial Results

13 days ago · globenewswire.com

Tarsus Reports Third Quarter 2026 Financial Results
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%

15 days ago · zacks.com

How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
My 'Eye' Is On Tarsus Pharmaceuticals

16 days ago · seekingalpha.com

My 'Eye' Is On Tarsus Pharmaceuticals
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

18 days ago · globenewswire.com

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

20 days ago · globenewswire.com

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

21 days ago · zacks.com

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$14.4
Miss -886.30%
REV
$194.57M
Beat +3.59%
Next Earnings
Feb 22, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$105.00
Upside
+33.45%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.